Goldman Sachs 46th Annual Global Healthcare Conference Call June 11, 2025 3:20 PM ETCompany ParticipantsTom Cavanaugh ...

Subcutaneous infliximab therapy alone is associated with higher immunogenicity than IV infliximab and an immunomodulator combined.

Dr. James Lee is a Clinician Scientist Group Leader at the Francis Crick Institute (London, UK) and an Honorary Consultant ...

Specific protein signatures could predict a future diagnosis of Crohn disease and ulcerative colitis, potentially enabling ...

The American College of Lifestyle Medicine (ACLM) has published the first clinical practice guideline to put lifestyle ...

The assessment of Crohn's disease activity through endoscopy is a cornerstone of both clinical management and research. In The Lancet Gastroenterology & Hepatology, Christopher Ma and colleagues ...

New research shows how metabolic activity and thus the communication between intestinal tissue and microbiome collapses ...

Welcome to the realm of irritable bowel syndrome (IBS), a prevalent and chronic disorder that affects over 1 billion ...

Based on this information, we explored new strategies for IBD treatment targeting the intestinal fungal group and its metabolites, such as fungal probiotics, antifungal drugs, diet therapy, and fecal ...

kuleuven.be Objective We evaluated the histamine 1 receptor antagonist ebastine as a potential treatment for patients with non-constipated irritable bowel syndrome (IBS) in a randomised, ...

Treatment naivety was defined as no prior treatment with IBD-related medications, including topical therapies. Previous treatments in patients who were not treatment-naïve included mostly topical ...

Physician's Weekly has compiled a collection of expert insights on inflammatory bowel disease, focusing on cancer rates and ...